Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Codexis Inc (CDXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 838,530
  • Shares Outstanding, K 53,240
  • Annual Sales, $ 50,020 K
  • Annual Income, $ -23,000 K
  • 36-Month Beta -1.68
  • Price/Sales 16.71
  • Price/Cash Flow N/A
  • Price/Book 55.50

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.35 +17.98%
on 06/28/18
16.80 -6.25%
on 06/21/18
+0.05 (+0.32%)
since 06/19/18
3-Month
10.90 +44.50%
on 05/01/18
16.80 -6.25%
on 06/21/18
+4.65 (+41.89%)
since 04/19/18
52-Week
4.80 +228.12%
on 08/04/17
16.80 -6.25%
on 06/21/18
+10.20 (+183.78%)
since 07/19/17

Most Recent Stories

More News
Codexis Appoints Dr. Hicham Alaoui, Veteran Drug Discoverer, as Vice President, Biotherapeutics Research & Development

Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Hicham Alaoui, Ph.D. to the newly created position of Vice President, Biotherapeutics Research & Development....

CDXS : 15.75 (unch)
Free Technical Research on Clovis Oncology and Three More Biotech Equities

Stock Research Monitor: CLSD, CDXS, and CHRS

CDXS : 15.75 (unch)
CLSD : 9.99 (-3.66%)
CLVS : 47.04 (+1.31%)
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114

Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered...

CDXS : 15.75 (unch)
New Research Coverage Highlights WPP, Codexis, Natural Resource Partners LP, Mercer International, Booking, and SINOPEC Shangai Petrochemical -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of WPP PLC (NYSE:WPP), Codexis,...

CDXS : 15.75 (unch)
SHI : 62.36 (-0.70%)
WPP : 74.60 (-2.37%)
NRP : 31.75 (-0.31%)
MERC : 17.67 (-0.14%)
BKNG : 2,010.60 (-0.66%)
Codexis to Present at Three Upcoming Investment Conferences

Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at three upcoming investment conferences:

CDXS : 15.75 (unch)
Cimpress Aims to Mitigate Risks by Decentralizing Operations

Cimpress' (CMPR) management has decentralized operations to improve accountability for customer satisfaction and capital returns, simplify decision-making and improve the speed of execution.

CMPR : 151.31 (+1.22%)
CDXS : 15.75 (unch)
KIGRY : 17.8100 (-3.73%)
HDS : 44.96 (+0.09%)
Here's Why You Should Add Sonoco (SON) to Your Portfolio Now

Sonoco's (SON) prospects remain bright on the back of solid earnings estimate revision activity as well as an upbeat guidance.

SON : 55.23 (+4.21%)
CDXS : 15.75 (unch)
AOS : 60.06 (+0.62%)
IEX : 140.67 (+1.14%)
Codexis Reports First Quarter 2018 Financial Results

Total revenues increase 76% to $14.0 million on sharply higher R&D revenue

CDXS : 15.75 (unch)
Porton Pharma Solutions and Codexis Launch Global Partnership

Codexis, Inc. (NASDAQ: CDXS) and Porton Pharma Solutions, Ltd. (SZSE: 300363) announce a strategic collaboration to deploy Codexis' world-leading biocatalyst technology within...

CDXS : 15.75 (unch)
EnzymeWorks, Inc. Retracts Prior Press Release

EnzymeWorks has been ordered by the United States District Court for the Northern District of California to retract its prior statements and press releases pertaining in any way to the settlement...

CDXS : 15.75 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CDXS with:

Business Summary

Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for the commercial manufacture of pharmaceuticals and fine chemicals. Codexis' proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective...

See More

Key Turning Points

2nd Resistance Point 16.15
1st Resistance Point 15.95
Last Price 15.75
1st Support Level 15.40
2nd Support Level 15.05

See More

52-Week High 16.80
Last Price 15.75
Fibonacci 61.8% 12.22
Fibonacci 50% 10.80
Fibonacci 38.2% 9.38
52-Week Low 4.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar